Compare PPG Industries, Inc. (PPG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Viatris Inc — how do they compare? PPG Industries, Inc. trades at $105.43 (market cap $23.36B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: PPG Industries, Inc. is the larger of the two by market cap, and PPG Industries, Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and Viatris Inc for 57 Days on average.
| PPG | VTRS | |
|---|---|---|
Market Cap | $23.36B | $20.12B |
Volume | 1,972,399 | 7,543,511 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $18.27 |
52-Week Low | $94.34 | $9.74 |
Typical Hold Time | 68 Days | 57 Days |
Enterprise Value | $29.22B | $32.24B |
Dividend Yield | 2.82% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG trades at $105.45, down 1.02% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 estimates but beating in Q1 2026. Fundamentals are solid with a P/E of 15.08, net income margin of 9.57%, and strong cash flow generation of $1.94B from operations in 2025. Recent news highlights margin pressures in the Automotive Refinish segment and upcoming Q3 2026 earnings on October 27.
The outlook is cautiously optimistic given analyst consensus favoring Buy with a $130 price target, implying 23% upside. Key opportunities include earnings growth and dividend stability, while risks involve segment-specific weakness and macroeconomic headwinds affecting demand. The stock's current valuation near support levels may attract value investors awaiting clearer earnings momentum.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
